Bristol-Myers Squibb

Latest Headlines

Latest Headlines

The top drug delivery partnerships of 2013

In the biotech and pharma industries, drug delivery is a crucial aspect of research and development. Finding new ways to deliver old drugs, ways to make a new drug more efficient or ways that make a...

Big Pharma superteam joins NIH to share data, discover new drugs

The National Institutes of Health has persuaded 10 rival drugmakers to briefly set aside their competitive spirits and collaborate on drug discovery projects in four major diseases, pooling their data and expertise to kick-start early-stage efforts.

Bristol-Myers is counting on DTC to keep driving Eliquis growth

Bristol-Myers Squibb says its Eliquis DTC campaign is doing its part to help get sales where the company wants them. Revenues for the anticoagulant may not be where many analysts expected they'd be when they talked the drug up as a future $3-billion-a-year blockbuster. But they are on the rise--thanks, in part, to the campaign, launched in September. And BMS says it's not stopping there.

Pace of BMS cancer trial leaves investors wary

When BMS said it would continue its mid-stage instead of diving into a late-stage program testing nivolumab with melanoma hit Yervoy, investors feared it could mean problems with the combo--and sent shares down nearly 6%.

Bristol-Myers impresses with trimmed-down costs, pumped-up sales

Bristol-Myers Squibb's got some pumped-up sales to go along with its slimmed-down focus. In the fourth quarter, revenue increases and decreased costs helped the company beat Wall Street's earnings estimates on the way to zeroing in on its new-look pharma model.

Bristol-Myers says it's open to dealmaking in the cancer field

Bristol-Myers Squibb says it's on the lookout for new deals, but that its focus will be on snapping up experimental treatments still in development instead of commercial products already on the market, according to a  Bloomberg  story.

UPDATED: FDA OKs AstraZeneca's long-delayed diabetes drug dapagliflozin

The FDA has handed AstraZeneca a green light to begin marketing dapagliflozin, its long-delayed SGLT2 diabetes drug, which will now try to defy the steadily dwindling expectations of market analysts. The treatment--the first new FDA drug approval for 2014--will be sold as Farxiga.

Bristol-Myers bails out of 'Diabetes Inc.' in $4.1B sell-out to AstraZeneca

When Bristol-Myers Squibb got out of the diabetes development business a couple of months ago, the logical follow-up question was this: Will the company bag diabetes sales, too? The answer is yes.

AstraZeneca will pay up to $4.1B for Bristol's share of their diabetes pact

As Bristol-Myers Squibb backs away from diabetes development, AstraZeneca has stepped up to buy its partner's stake in the pair's joint venture, agreeing to hand over as much as $4.1 billion in a move that will add some promise to a thinning pipeline.

AstraZeneca, BMS pull Forxiga in Germany in snit over pricing

AstraZeneca and Bristol-Myers Squibb look to be feeling good about the future of their diabetes drug Forxiga. The drugmakers have yanked the diabetes treatment from the market in Germany because they couldn't get the reimbursement they wanted from medical insurers. The nose-thumbing move came the day after an FDA panel recommended the drug for approval in the U.S.